News
FEMY
1.420
+1.43%
0.020
Press Release: Femasys Announces Financial -2-
Dow Jones · 1d ago
Press Release: Femasys Announces Financial Results for Quarter Ended September 30, 2026 and Provides Corporate Update
Dow Jones · 1d ago
Femasys Insider Purchases Yet To Pay Off Regardless Of Recent Strength
Simply Wall St · 3d ago
Weekly Report: what happened at FEMY last week (1102-1106)?
Weekly Report · 6d ago
Rare Stock Picks In October 2026 - From 14 Discerning Analysts
Seeking Alpha · 11/04 13:00
Femasys Announces Board Director Appointment and Resignation
TipRanks · 11/02 22:11
Weekly Report: what happened at FEMY last week (1026-1030)?
Weekly Report · 11/02 09:24
*Femasys Appoints John Moorhead to Bd of Directors
Dow Jones · 10/30 13:01
Press Release: Femasys Appoints John Moorhead to Board of Directors
Dow Jones · 10/30 13:00
Weekly Report: what happened at FEMY last week (1019-1023)?
Weekly Report · 10/26 09:24
Biotech Stocks Move Higher: MBRX Gains 15%, FEMY Rises 7%, RVMD Advances 7%, MYGN Surges Over 40%
NASDAQ · 10/20 18:49
Femasys Taps SandsRx Pharmacy To Coordinate Medications For FemaSeed Patients; Stock Up
NASDAQ · 10/20 15:24
Femasys teams with SandsRx Pharmacy to support FemaSeed
TipRanks · 10/20 13:11
Weekly Report: what happened at FEMY last week (1012-1016)?
Weekly Report · 10/19 09:24
Femasys Doubles Enrollment Sites For FemBloc Pivotal Study; Stock Down
NASDAQ · 10/14 15:11
Femasys doubles enrolling sites in FemBloc FINALE Pivotal Trial
TipRanks · 10/14 13:16
Femasys Doubles Number Of Enrolling Facilities To 12 In Its FemBloc FINALE Pivotal Study Across U.S.
Benzinga · 10/14 13:01
Femasys: Launch Is Funded. If The Sales Force Delivers, Then The Company Is In Tall Cotton.
Seeking Alpha · 10/14 05:26
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 10/13 12:05
Weekly Report: what happened at FEMY last week (1005-1009)?
Weekly Report · 10/12 09:26
More
Webull provides a variety of real-time FEMY stock news. You can receive the latest news about FEMASYS INC through multiple platforms. This information may help you make smarter investment decisions.
About FEMY
Femasys Inc. is a biomedical company. The Company is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. It also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.